{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:46Z","timestamp":1791595366995,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.exphem.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:59:50Z","timestamp":1698674390000},"page":"104125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-8356","authenticated-orcid":false,"given":"David M.","family":"Foureau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nury M.","family":"Steuerwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2019-2252","authenticated-orcid":false,"given":"Lawrence J.","family":"Druhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda R.","family":"Avalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Copelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-0929","authenticated-orcid":false,"given":"Bei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-8455","authenticated-orcid":false,"given":"Tamara","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5674-6408","authenticated-orcid":false,"given":"Steven","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3848-6136","authenticated-orcid":false,"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2023.10.004_bib0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/CCO.0000000000000209","article-title":"Primary refractory diffuse large B cell lymphoma in the rituximab era","volume":"27","author":"Sarkozy","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0002","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","article-title":"Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?","volume":"2017","author":"Davies","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2023.10.004_bib0003","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.10.004_bib0004","doi-asserted-by":"crossref","first-page":"27676","DOI":"10.18632\/oncotarget.8507","article-title":"Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients","volume":"7","author":"Marini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2023.10.004_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0006","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0007","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.10.004_bib0008","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.exphem.2023.10.004_bib0009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1365-2036.1996.22164025.x","article-title":"Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies","volume":"10","author":"Brattsand","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.exphem.2023.10.004_bib0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","volume":"74","author":"Alizadeh","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2023.10.004_bib0011","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3389\/fonc.2019.01223","article-title":"IL-6 and IL-8 are linked with myeloid-derived suppressor cell accumulation and correlate with poor clinical outcomes in melanoma patients","volume":"9","author":"Tobin","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.697405","article-title":"Myeloid-derived suppressor cells as a potential biomarker and therapeutic target in COVID-19","volume":"12","author":"Rowlands","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0013","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","article-title":"Tumor necrosis factor-alpha blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation","volume":"38","author":"Sade-Feldman","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2023.10.004_bib0014","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4049\/jimmunol.1600759","article-title":"Kinetics of myeloid-derived suppressor cell frequency and function during simian immunodeficiency virus infection, combination antiretroviral therapy, and treatment interruption","volume":"198","author":"Dross","year":"2017","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-1060-2_6","article-title":"High-dimensional phenotyping of human myeloid-derived suppressor cells\/tumor-associated macrophages in tissue by mass cytometry","volume":"2236","author":"Ferrant","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0016","article-title":"Prognostic significance of systemic immune-inflammation index in patients with diffuse large B-cell lymphoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.exphem.2023.10.004_bib0017","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1005902120612","article-title":"Down-regulation of transforming growth factor-beta and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs","volume":"39","author":"Naganuma","year":"1998","journal-title":"J Neurooncol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2301740X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2301740X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:39:41Z","timestamp":1759567181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2301740X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":17,"alternative-id":["S0301472X2301740X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.10.004","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of myeloid-derived suppressor cells and systemic inflammation in newly diagnosed diffuse large B cell lymphoma treated with chemoimmunotherapy","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104125"}}